Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Jung's paternity reveal exposes where Korea stands on extramarital babies

    Jung's paternity reveal exposes where Korea stands on extramarital babies
  2. 2

    Samsung entangled in legal risks amid calls for drastic reform

    Samsung entangled in legal risks amid calls for drastic reform
  3. 3

    Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul

    Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul
  4. 4

    [Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'

    [Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'
  5. 5

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
  1. 6

    [Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle

    [Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle
  2. 7

    Prosecutors seek 5-year prison term for Samsung chief in merger retrial

    Prosecutors seek 5-year prison term for Samsung chief in merger retrial
  3. 8

    UN talks on plastic pollution treaty begin with grim outlook

    UN talks on plastic pollution treaty begin with grim outlook
  4. 9

    K-pop fandoms wield growing influence over industry decisions

    K-pop fandoms wield growing influence over industry decisions
  5. 10

    Korea's auto industry braces for Trump’s massive tariffs in Mexico

    Korea's auto industry braces for Trump’s massive tariffs in Mexico
피터빈트

Medytox Q2 earnings to beat expectations

By Korea Herald

Published : July 19, 2016 - 16:01

    • Link copied

[THE INVESTOR] Korean biopharmaceutical firm Medytox is likely to post stronger-than-expected earnings in the second quarter on robust growth of its hyaluronic acid dermal filler brand Neuramis, a local brokerage NH Investment & Securities said on July 19.

“Medytox’s Q2 sales and operating profit were estimated at 31.2 billion won (US$27.43 million) and 18.4 billion won, respectively, up 42.8 percent and 31.4 percent on-year,” said Lee Seung-ho, an analyst at the securities firm. 


NH Investment & Securities retained its buy rating for Medytox and a price target of 640,000 won. Medytox’s stock gained 0.29 percent to 421,100 won as of 2:25 p.m.

By Park Han-na (hnpark@heraldcorp.com)

More from Headlines